MDSpire - Summary
Clinical Guidelines

Radiotherapy May Reduce Risk of Lymphedema in Patients With Breast Cancer More Effectively Than Surgery

These results come from the pilot phase of the phase III ADARNAT randomized international clinical trial, which is investigating whether axillary radiotherapy has a lower risk of lymphedema than axill...

Share

Recent findings from the 15th European Breast Cancer Conference highlight the potential of axillary radiotherapy (ART) as an alternative to axillary lymph node dissection (ALND) for breast cancer patients post-neoadjuvant therapy. Spearheaded by Dr. Amparo Garcia-Tejedor, a clinical trial (ADARNAT) indicates ART may reduce lymphedema risk while effectively targeting cancer cells. With a follow-up of 2 years, this approach shows promise in maintaining quality of life by minimizing surgical invasiveness, though long-term data is still required to ensure reliable outcomes.

Original Source(s)

Radiotherapy May Reduce Risk of Lymphedema in Patients With Breast Cancer More Effectively Than Surgery

  • by The ASCO Post Staff

  • March 30, 2026

Related Content

New Frontiers in Neuroendocrine Tumors: Enhancing Diagnosis, Treatment, and Patient Outcomes

Breast Cancer Recurrence Remains Low—Even After 10 Years—With Radiotherapy Tailored to Patient’s Individual Risk

“The results of our study show that tailoring the extent of radiotherapy according to how well the chemotherapy has worked to treat cancer in the lymph nodes leads to very low and reassuring recurrenc...

Therapeutic Advances in Metastatic Melanoma: TILs, ImmTACs, and Targeted Therapies